Develops minimally invasive robotic surgery systems designed to enhance surgeon capabilities and improve patient outcomes.
Asensus Surgical, Inc., a pioneering medical device company, focuses on advancing minimally invasive surgery (MIS) through innovative robotics technology. Operating in the United States, Europe, and Asia, the company is dedicated to transforming surgical practices by digitalizing the interface between surgeons and patients. This approach heralds a new era of Performance-Guided surgery, providing surgeons with enhanced clinical intelligence to consistently achieve superior outcomes and establish a new standard in surgical precision.
At the forefront of Asensus Surgical's portfolio is the Senhance Surgical System, a state-of-the-art multi-port robotic surgery platform. This system enables surgeons to control up to four robotic arms and a camera during laparoscopic procedures, enhancing precision and efficiency in surgical operations. The company also offers a range of instruments and products tailored for MIS, including 3mm diameter instruments, hooks, and articulating instruments. Additionally, the Senhance Ultrasonic System delivers controlled energy for tissue ligation and division, further supporting minimally invasive surgical techniques.
Founded in 2006 and headquartered in Durham, North Carolina, Asensus Surgical, Inc. was formerly known as TransEnterix, Inc. before rebranding in February 2021. With a commitment to innovation and improving patient outcomes, the company continues to lead the field of robotic surgery, collaborating with healthcare professionals globally to advance the capabilities of surgical technology.